MLP Saglik Hizmetleri (MPARK) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
18 May, 2026Executive summary
Revenue grew by 6% year-over-year in Q1 2026, reaching TL 16,252 million, supported by private medical insurance.
EBITDA increased by 25% year-over-year to TL 4,810 million, driven by a favorable revenue mix and efficiency initiatives.
Net profit rose 11.5% year-over-year to TL 1,862 million, aided by monetary gains and deferred tax income.
The hospital network expanded to 34 hospitals across 13 cities in Türkiye.
Total assets stood at TRY 89,936.2 million as of March 31, 2026.
Financial highlights
Outpatient and inpatient revenues grew by 6.9% and 4.4% year-over-year, respectively.
EBITDA margin improved to 29.6% from 25.0% in Q1 2025.
Gross profit increased to TRY 4,473.3 million from TRY 4,230.1 million year-over-year.
Operating profit was TRY 2,516.8 million, down from TRY 2,953.5 million in Q1 2025.
Finance expenses rose to TRY 1,371.6 million from TRY 1,248.3 million year-over-year.
Outlook and guidance
Management expects continued growth, supported by network expansion and efficiency measures.
The Group continues to evaluate the effects of new and revised Turkish Financial Reporting Standards effective from 2026 and 2027.
Latest events from MLP Saglik Hizmetleri
- Revenue up 6%, EBITDA up 14.8%, net profit down 18.8% amid expansion and acquisitions.MPARK
Q4 202516 Mar 2026 - Revenue and EBITDA rose, but net profit fell as expansion and acquisitions drove costs higher.MPARK
Q3 202526 Nov 2025 - Revenue up 22% to 39.7B TL, net profit down 15.6%, four hospitals acquired.MPARK
Q4 202418 Aug 2025 - Revenue and EBITDA rose, but net profit fell as costs, borrowings, and capex surged.MPARK
Q2 202518 Aug 2025 - Strong revenue and profit growth driven by domestic demand and network expansion.MPARK
Q3 202413 Jun 2025 - Revenue and EBITDA surged in H1 2024, driven by insurance and hospital expansion.MPARK
H1 202413 Jun 2025 - Revenue and profit surged, but higher capex and inflation risks impacted cash flow.MPARK
Q1 20256 Jun 2025